AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Trading 08-07 14:55:07 EDT

6.65

+0.12

+1.76%

High6.69	Low6.35	Vol3.40M
Open6.65	D1 Closing6.53	Amplitude5.21%
Mkt Cap2.03B	Tradable Cap1.36B	Total Shares305.26M
T/O22.05M	T/O Rate1.66%	Tradable Shares205.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":6.645,"timestamp":1786128907096,"preClose":6.53,"halted":0,"volume":3397279,"delay":0,"changeRate":0.017611026033690556,"floatShares":204999999,"shares":305264947,"eps":-0.54,"marketStatus":"Trading","change":0.115,"latestTime":"08-07 14:55:07 EDT","open":6.65,"high":6.69,"low":6.35,"amount":22046742.6299584,"amplitude":0.052067,"askPrice":6.65,"askSize":806,"bidPrice":6.64,"bidSize":1297,"shortable":3,"etf":0,"ttmEps":-0.54,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786132800000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":6.53,"preHourTrading":{"tag":"盘前","latestPrice":6.61,"preClose":6.53,"latestTime":"09:29 EDT","volume":96523,"amount":637477.9007834999,"timestamp":1786109354507,"change":0.08,"changeRate":0.012251,"amplitude":0.027412},"postHourTrading":{"tag":"盘后","latestPrice":6.4514,"preClose":6.53,"latestTime":"19:57 EDT","volume":303970,"amount":1982798.1111,"timestamp":1786060630577,"change":-0.0786,"changeRate":-0.012037,"amplitude":0.018377},"volumeRatio":0.799314,"impliedVol":1.0051,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/ABCL/tweets","defaultTab":"tweets","newsList":[{"id":"2657864752","title":"Piper Sandler Remains a Buy on AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657864752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657864752?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:28","pubTimestamp":1786116500,"startTime":"0","endTime":"0","summary":"In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on AbCellera Biologics, with a price target of $12.00. Bratz...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696303","title":"AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696303","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696303?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:36","pubTimestamp":1786073806,"startTime":"0","endTime":"0","summary":"AbCellera Biologics jumped 10.3% to US$6.53 today, a sharp move for a stock that came into the print with a mixed recent run, up over the past week but down over the past month. The market is reacting to one thing above all else: the company is leaning hard into a high cash burn and deeper quarterly loss to fund its antibody pipeline, backed by a reported US$567 million cash pile and more than US$675 million of available liquidity.\nThe question now is whether that liquidity cushion really...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-stock-jumps-as-cash-burn-fuels-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-stock-jumps-as-cash-burn-fuels-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680106","title":"OmniAb Q2 Revenue Beats Analyst Estimates, Outlook Raised","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680106","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680106?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:40","pubTimestamp":1786048821,"startTime":"0","endTime":"0","summary":"OmniAb Q2 revenue beats analyst estimates, outlook raisedOverviewUS discovery research tech firm's Q2 revenue rose sharply, beating analyst expectationsNet loss for Q2 narrowed compared to same period","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121","OABI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657151630","title":"AbCellera Biologics is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2657151630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657151630?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:24","pubTimestamp":1786026240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863690","title":"AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863690?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017636,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Steven Seedhouse reiterated a Buy rating on AbCellera Biologics yesterday and set a price target of $12.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-gets-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-gets-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657577853","title":"AbCellera Biologics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657577853","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657577853?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:57","pubTimestamp":1785974262,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. reports results for the quarter ended June 30 - Earnings SummaryAbCellera Biologics Inc.ABCL.OQreported a quarterly adjusted loss of 18 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657557845","title":"AbCellera Q2 FY26 Net Loss Widens to USD 55.4 Million; Revenue Drops to USD 4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657557845","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657557845?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:24","pubTimestamp":1785961467,"startTime":"0","endTime":"0","summary":"AbCellera Q2 FY26 net loss widens to USD 55.4 million; revenue drops to USD 4.1 millionAbCellera Biologics posted Q2 2026 revenue of USD 4.1 million, down 76.29% from a year earlier.Net loss widened t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL5Yk2Wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657014527","title":"AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657014527","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657014527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:07","pubTimestamp":1785960461,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of $(0.12) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60969358/abcellera-biologics-q2-eps-0-18-misses-0-14-estimate-sales-4-050m-miss-7-784m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520376","title":"AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520376","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520376?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:06","pubTimestamp":1785960363,"startTime":"0","endTime":"0","summary":"BRIEF-AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 MillionAug 05 (Reuters) - AbCellera Q2 net income USD -55.4 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXRK9RVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520844","title":"Press Release: AbCellera Reports Q2 2026 Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520844?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:05","pubTimestamp":1785960300,"startTime":"0","endTime":"0","summary":"--  ABCL386 and ABCL688 are progressing through IND-enabling activities.--  Announced collaboration with Jazz Pharmaceuticals plc to discover and. gastrointestinal cancers and other solid tumors. AbCellera is receiving. $84 million in total upfront payments, with $56 million for the first two. research programs and $28 million for a third program, which will. initiate within 12 months. AbCellera is eligible to receive up to $792. million per program in option fees and development, regulatory, and. commercial sales milestone payments along with tiered royalties on net. sales ranging from mid-single digits to low double digits.--  Completed dosing for the Phase 1 study of ABCL575, with top-line data. --  Generated a net loss of $55.4 million, compared to a net loss of $34.7. marketable securities, providing over $675 million in total available. AbCellera will receive $28 million in total upfront payments and is. eligible to receive preclinical, development, regulatory, and commercial. mi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656123307","title":"Abcellera Biologics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656123307","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656123307?lang=en_us&edition=fundamental","pubTime":"2026-08-04 05:35","pubTimestamp":1785792906,"startTime":"0","endTime":"0","summary":"Abcellera Biologics Inc <ABCL.OQ> expected to post a loss of14cents a share - Earnings PreviewAbcellera Biologics IncABCL.OQABCL.Ois expected to  show a fall in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402IP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102468556","title":"Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive","url":"https://stock-news.laohu8.com/highlight/detail?id=1102468556","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102468556?lang=en_us&edition=fundamental","pubTime":"2026-07-30 01:51","pubTimestamp":1785347514,"startTime":"0","endTime":"0","summary":"Abstract AbCellera Biologics will report fiscal second-quarter 2026 results on August 05, 2026 Post Market; this preview summarizes consensus and company guidance on revenue, margins, net income, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655646568","title":"AbCellera Partners with Vertex to Develop Multispecific T-cell Engagers for Autoimmune Diseases, Other Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2655646568","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655646568?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:04","pubTimestamp":1785323076,"startTime":"0","endTime":"0","summary":"AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditionsAbCellera entered a collaboration with Vertex to discover multispecific T-cell engagers","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL2LJq5y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655610958","title":"Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2655610958","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655610958?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUABN5JGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","LU2236285917.USD","IE00B2B36J28.USD","IBBQ","LU0109394709.USD","LU2462157665.USD","LU1093756168.USD","IDNA","LU0234570918.USD","ABCL","IE00B894F039.SGD","LU1093756325.SGD","IE0009355771.USD","IE0002270589.USD","LU0889565916.HKD","LU2456880835.USD","IE00B19Z3B42.SGD","VRTX","LU2362540622.SGD","IBB","LU0256863811.USD","BIB","LU1069344957.HKD","SGXZ57979304.SGD","BK4585","LU2237438978.USD","TBXU","IE00BJJMRZ35.SGD","IE00BZ9MQY76.HKD","BK4121","LU2362541513.USD","LU0432979614.USD","IE00B19Z9Z06.USD","LU2324357040.USD","LU1674673691.USD","BBH","PBE","SG9999013999.USD","LU1035775433.USD","GNMX","IE00B4R5TH58.HKD","LU0061475181.USD","IE00B19Z3581.USD","LU1585245621.USD","BK4535","LU1430594728.SGD","IE00BJT1NW94.SGD","LU1778281490.HKD","SG9999001176.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655340864","title":"Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2655340864","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655340864?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUABN5JGH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0061475181.USD","LU0256863811.USD","LU1674673428.USD","BK4585","IBBQ","IE00BZ9MQY76.HKD","LU0889565916.HKD","LU0079474960.USD","TBXU","IE00BFTCPJ56.SGD","VRTX","BK4567","BBH","GNMX","IE0002270589.USD","LU1093756325.SGD","IE00B19Z9P08.USD","LU1069344957.HKD","IE00B19Z3581.USD","IE0002141913.USD","LU0234570918.USD","LU0417517546.SGD","PBE","IE00B19Z3B42.SGD","LU1674673691.USD","IDNA","IE00B19Z9Z06.USD","LU0058720904.USD","LU0289739699.SGD","LU1585245621.USD","LU0109394709.USD","LU2417539215.USD","BK4533","SG9999001176.USD","LU2237438978.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0432979614.USD","ABCL","LU2236285917.USD","LU2362540622.SGD","LU2362541513.USD","LU2456880835.USD","IBB","BIB","LU1035775433.USD","SGXZ57979304.SGD","BK4121","LU0320765992.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655319864","title":"Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2655319864","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655319864?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUABN5JGH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU2236285917.USD","LU2237438978.USD","IE0009355771.USD","IE00B894F039.SGD","LU2462157665.USD","BK4139","LU2362540622.SGD","BBH","LU2324357040.USD","IE00B4R5TH58.HKD","ABCL","LU0417517546.SGD","LU1778281490.HKD","LU0234570918.USD","LU0432979614.USD","LU1430594728.SGD","VRTX","BIB","SG9999001176.SGD","IE0002270589.USD","IE00B2B36J28.USD","IE00B19Z3B42.SGD","BK4567","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","SG9999013999.USD","LU0061475181.USD","LU0079474960.USD","LU0889565916.HKD","LU1585245621.USD","GNMX","IBBQ","BK4532","LU0823416689.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","TBXU","IDNA","BK4535","IBB","LU0320765992.SGD","IE00B19Z9Z06.USD","LU2456880835.USD","PBE","LU1674673691.USD","LU1674673428.USD","BK4533","BK4588","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652295650","title":"Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652295650","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652295650?lang=en_us&edition=fundamental","pubTime":"2026-07-20 13:18","pubTimestamp":1784524716,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma, as an independent director to its Board, adding deep experience in clinical development and commercialization across oncology and women’s and men’s health.\nHer track record in advancing therapies from early trials to market and guiding companies through major acquisitions may influence how investors view AbCellera’s governance and execution capabilities.\nNext, we’ll examine how Dr. Seely’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/does-abcelleras-new-board-appointment-reframe-its-execution","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/does-abcelleras-new-board-appointment-reframe-its-execution","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","ABCL","BK4535","BK4121","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652283609","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652283609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652283609?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:30","pubTimestamp":1784291419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM), AbCellera Biologics (ABCL) and DBV Te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-abcellera-biologics-abcl-and-dbv-technologies-sa-american-dbvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-abcellera-biologics-abcl-and-dbv-technologies-sa-american-dbvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4121","AFG","BK4581","LU0053671581.USD","LU0889565916.HKD","HCSG","DBV","BK4535","XLV","BK4588","BK4137","BK4107","LU0320765992.SGD","LU0128526141.USD","BK4139","BK4117","BK4585","LABU","LU0029874061.USD","ABCL","XBI","INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651495048","title":"Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651495048?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:20","pubTimestamp":1784146809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alumis Inc. (ALMS) and AbCellera Biologics (ABCL) wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","LU0029874061.USD","XLV","LU0128526141.USD","BK4535","XBI","ALMS","BK4585","HCSG","ABCL","BK4007","BK4121","BK4581","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975626","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975626?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:05","pubTimestamp":1783613111,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 3,839 calls trading, 1.1x expected, and implied vol increasing over 2 points to 114...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.1476},{"period":"1month","weight":-0.1508},{"period":"3month","weight":0.2462},{"period":"6month","weight":1.0665},{"period":"1year","weight":0.585},{"period":"ytd","weight":0.9094}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.5,"avgChangeRate":0.144975},{"month":7,"riseRate":0.5,"avgChangeRate":-0.006532},{"month":8,"riseRate":0.5,"avgChangeRate":-0.043512},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}